Cargando…

Vimentin expression status is a potential biomarker for brain metastasis development in EGFR-mutant NSCLC patients

BACKGROUND: Despite advances in systemic therapy and improvements in survival for advanced epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), brain metastasis (BM) remains a poor outcome. Previous studies on risk factors for BM occurrence included unselected patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teocharoen, Rattanawadee, Ruangritchankul, Komkrit, Vinayanuwattikun, Chanida, Sriuranpong, Virote, Sitthideatphaiboon, Piyada
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947392/ https://www.ncbi.nlm.nih.gov/pubmed/33718022 http://dx.doi.org/10.21037/tlcr-20-1020

Ejemplares similares

Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer
por: Sitthideatphaiboon, Piyada, et al.
Publicado: (2022)

Prognostic factors in completely resected lymph-node-negative pulmonary adenocarcinoma
por: Pakvisal, Nussara, et al.
Publicado: (2022)

Effects of Complementary and Alternative Medicine on Chemotherapy Delivery in Thai Patients
por: Rabiltossaporn, Chawanya, et al.
Publicado: (2021)

A prospective randomized study comparing the efficacy between povidone-iodine gargling and benzydamine hydrochloride for mucositis prevention in head and neck cancer patients receiving concurrent chemoradiotherapy
por: Kannarunimit, Danita, et al.
Publicado: (2023)

Metachronous Brain Metastasis in patients with EGFR-mutant NSCLC indicates a worse prognosis
por: Ouyang, Wen, et al.
Publicado: (2020)

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
por: Ju, Jia-Shiuan, et al.
Publicado: (2023)

MCM-2, Ki-67, and EGFR downregulated expression levels in advanced stage laryngeal squamous cell carcinoma
por: Vivatvakin, Sarocha, et al.
Publicado: (2021)

Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study
por: Thongprasert, Sumitra, et al.
Publicado: (2019)

Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models
por: Zhang, Yuhan, et al.
Publicado: (2021)

Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis
por: Yan, Weiwei, et al.
Publicado: (2019)

Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients
por: Yan, Dan
Publicado: (2023)

The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients
por: Noronha, Vanita, et al.
Publicado: (2014)

Epithelial-mesenchymal transition mediates anoikis resistance and enhances invasion in pleural effusion-derived human lung cancer cells
por: CHUNHACHA, PREEDAKORN, et al.
Publicado: (2013)

Effect of the ERCC1 (C118T) Polymorphism on Treatment Response in Advanced Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy
por: Kaewbubpa, Walennee, et al.
Publicado: (2016)

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
por: Tan, Wan-Ling, et al.
Publicado: (2018)

EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients
por: Karachaliou, Niki, et al.
Publicado: (2019)

Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC
por: Yu, Min, et al.
Publicado: (2022)

Structure-based classification predicts drug response in EGFR-mutant NSCLC
por: Robichaux, Jacqulyne P., et al.
Publicado: (2021)

Uncommon EGFR-Mutant NSCLC—One Drug Does Not Fit All
por: Wang, Yang, et al.
Publicado: (2023)

Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib
por: Kudo, Kenichiro, et al.
Publicado: (2020)

Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases
por: Saida, Yu, et al.
Publicado: (2019)

Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway
por: Hou, Xiaoying, et al.
Publicado: (2018)

Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases
por: Zhang, Guowei, et al.
Publicado: (2017)

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
por: Tan, Wan-Ling, et al.
Publicado: (2018)

IgG4-related pseudo-tumor of the kidney and multiple organ involvement mimicked malignancy
por: Surintrspanont, Jerasit, et al.
Publicado: (2019)

USP17 is required for trafficking and oncogenic signaling of mutant EGFR in NSCLC cells
por: McCann, Aidan P., et al.
Publicado: (2018)

Characteristics of and Treatment Strategies for Advanced EGFR-Mutant NSCLC With Concomitant BRAF Variations
por: Wei, Xue-Wu, et al.
Publicado: (2022)

Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
por: Ye, Qiuyue, et al.
Publicado: (2023)

A novel function for vimentin: the potential biomarker for predicting melanoma hematogenous metastasis
por: Li, Man, et al.
Publicado: (2010)

Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment
por: Charoenchokthavee, Wanaporn, et al.
Publicado: (2016)

Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients
por: Charoenchokthavee, Wanaporn, et al.
Publicado: (2017)

Incidence of oxaliplatin hypersensitivity reaction among colorectal cancer patients: A 5-year retrospective study
por: Palapinyo, Sirinoot, et al.
Publicado: (2022)

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
por: Arasada, Rajeswara Rao, et al.
Publicado: (2018)

Prognostic Value of BIM Deletion in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs: A Meta-Analysis
por: Lv, Fangfang, et al.
Publicado: (2021)

Mitochondrial translocation of EGFR regulates mitochondria dynamics and promotes metastasis in NSCLC
por: Che, Ting-Fang, et al.
Publicado: (2015)

BECN1 promotes the migration of NSCLC cells through regulating the ubiquitination of Vimentin
por: Cheng, Zhujun, et al.
Publicado: (2019)

Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC
por: Peters, T. L., et al.
Publicado: (2021)

Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia
por: How, Soon Hin, et al.
Publicado: (2022)

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells
por: Wu, Hong, et al.
Publicado: (2015)

A novel TRPM7/O-GlcNAc axis mediates tumour cell motility and metastasis by stabilising c-Myc and caveolin-1 in lung carcinoma
por: Luanpitpong, Sudjit, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ce5fj5jquj7blm7laac8hu6429